HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

Tirzepatide and semaglutide linked to fewer heart attacks, strokes and deaths in diabetes

Louis Nervegna · Dec 09, 2025 · ♥ 6 reactions · 1 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Insulin resistance & diabetesHeart attack, stroke & procedures
AI summary & key facts

Louis shares a Mass General Brigham report of a Nature Medicine study, presented at AHA 2025, of nearly 1 million adults with type 2 diabetes in which both tirzepatide and semaglutide were associated with lower risk of heart attack, stroke and death.

#glp1HD #cvdHD #strokeHD #mghHD #diabetesHD

Research cited

New research from Mass General Brigham shows both tirzepatide and semaglutide help protect heart health. In a study of nearly 1M adults with type 2 diabetes, both medications were linked to lower risk of heart attack, stroke, and death. Findings were published in Nature Medicine and presented at the American Heart Association 2025 Scientific Sessions. Learn more: Mass General Brigham News (news.massgeneralbrigham.org)

No photo description available.
← newer: Niacin inhibited vascular calcification in mice via SIRT1/SIolder: Urolithin A from pomegranate, walnuts and berries acts as a →